Income Statement Presentation 2023

2022: Diagnostics Division highlights Strong growth despite a high base in 2021 CHFbn YoY CER growth Core Lab 1,3 Point of Care³ Molecular Lab³ Diabetes Care Pathology Lab +11% 0.0 2.0 -2% 4.0 +17% -15% +6% · Immunodiagnostics (+7%) • Clinical Chemistry (+9%) • Custom biotech (-7%) • POC Immunodiagnostics (+22%) POC Molecular³ (+22%) • Virology (-20%) • . qPCR&NAP (-31%) • Blood glucose monitoring (-3%) • ⚫ Insulin delivery systems (+5%) • Advanced staining (+9%) EMEA² Asia-Pacific North America Latin America • Companion diagnostics (+25%) 6.0 8.0 CER-Constant Exchange Rates; POC-point of care; 1 Underlying growth of Core Lab excluding Roche Information Solutions: +6%; 2 EMEA-Europe, Middle East and Africa; 3 Sales in Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23mCHF, Q4 21=20mCHF. 38 30 Roche

View entire presentation